POC

Siyata Mobile Inc. to Showcase Portfolio at IWCE 2024

Retrieved on: 
Monday, March 11, 2024

VANCOUVER, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (NASDAQ: SYTA ) (“Siyata” or the “Company”), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that the Company will host an exhibitor's booth at the International Wireless Communications Expo ("IWCE") 2024 in partnership with Verizon, in Booth # 608.

Key Points: 
  • VANCOUVER, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (NASDAQ: SYTA ) (“Siyata” or the “Company”), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories, today announced that the Company will host an exhibitor's booth at the International Wireless Communications Expo ("IWCE") 2024 in partnership with Verizon, in Booth # 608.
  • Siyata will be showcasing its SD7 Mission Critical PTT Handset, its VK7 Vehicle Kit, and its accessories.
  • IWCE 2024 takes place March 25-28 at the Orange County Convention Center in Orlando, Florida.
  • The Siyata Mobile booth is in the Verizon Partner Pavilion, adjacent to the Verizon Frontline Exhibit, in Halls D and E of the Orange County Convention Center.

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Wednesday, March 6, 2024

THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has commenced patient enrollment for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to commence enrollment of the PoC human clinical trial and take another step toward validating our clinical and regulatory plans for our technology,” commented Lori Bisson, Chief Executive Officer of Autonomix.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.
  • Confirmation of suitability will be affirmed by the primary oncology service caring for the patients.
  • Up to 5 additional patients will be included and treated according to protocol to ensure the physician’s familiarity with the procedure.

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Thursday, February 29, 2024

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

Communications Service Providers Modernize Networks via Broadcom, Partner Ecosystem Collaboration

Retrieved on: 
Tuesday, February 27, 2024

BARCELONA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Today at Mobile World Congress (MWC) 2024, VMware, recently acquired by Broadcom Inc. , highlighted Communications Service Providers (CSPs) deploying VMware Telco Cloud and VMware Service Management and Orchestration (SMO) solutions as well as co-innovations with its partner ecosystem to help global CSPs to modernize their networks and create monetizable services quickly.

Key Points: 
  • BARCELONA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Today at Mobile World Congress (MWC) 2024, VMware, recently acquired by Broadcom Inc. , highlighted Communications Service Providers (CSPs) deploying VMware Telco Cloud and VMware Service Management and Orchestration (SMO) solutions as well as co-innovations with its partner ecosystem to help global CSPs to modernize their networks and create monetizable services quickly.
  • “We’ve successfully enabled our customers to modernize their networks from the core to the RAN with VMware Telco Cloud Platform,” said Sanjay Uppal, vice president and general manager, Software-Defined Edge Division, Broadcom.
  • Co-Innovation with Partner Ecosystem to Fuel Core, RAN and RIC Advancements
    VMware continues to advance its innovation efforts in collaboration with a broad partner ecosystem that helps fuel multi-vendor networks.
  • VMware’s Software-Defined Edge solutions for communication service providers and enterprises are on display at its Mobile World Congress stand – Hall 3.0, Stand 3M11.

Broadcom and Vodafone Demonstrate Network Programmability to Optimize Network Performance for Short-Form Video Content

Retrieved on: 
Tuesday, February 27, 2024

The joint effort showcases the benefits of applying network programmability and intelligence into the Radio Access Network (RAN), enhancing overall performance for customers.

Key Points: 
  • The joint effort showcases the benefits of applying network programmability and intelligence into the Radio Access Network (RAN), enhancing overall performance for customers.
  • The emergence and rapid expansion of short-form video content is placing greater capacity demands on Communication Service Provider (CSP) networks globally.
  • To address these network challenges, Vodafone is implementing innovative solutions aimed at continuously enhancing the network performance for its customers.
  • The Network Programmability PoC will be showcased in both the VMware stand as well as Vodafone’s located in Hall 3 Stand 3E11.

Siyata Mobile Receives 1000 Unit Order for UV350 Devices

Retrieved on: 
Thursday, February 22, 2024

LOS ANGELES, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW) ("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories, announces it has received a purchase order for 1,000 units of its UV350 all-in-one in vehicle fleet communication devices from an international EMS provider.

Key Points: 
  • LOS ANGELES, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW) ("Siyata" or the "Company"), a global developer and vendor of Push-to-Talk over Cellular (PoC) handsets and accessories, announces it has received a purchase order for 1,000 units of its UV350 all-in-one in vehicle fleet communication devices from an international EMS provider.
  • The Company expects to deliver the units in the current, first quarter of 2024.
  • Siyata CEO, Marc Seelenfreund, commented, "Serving the First Responder vertical is foundational to our business, and this order reinforces our prominent position within the space.
  • Our UV350 is essentially a smartphone that is specifically designed for fleet vehicles to optimize mobile communications while driving.

BaaS provider Morpheus Labs to Integrate Coinweb's Cutting-Edge Technology and Unveils Strategic Partnership

Retrieved on: 
Thursday, February 22, 2024

The partnership between Morpheus Labs and Coinweb presents a compelling opportunity for both parties.

Key Points: 
  • The partnership between Morpheus Labs and Coinweb presents a compelling opportunity for both parties.
  • Morpheus Labs will integrate Coinweb's cutting-edge tools into its platform, providing its diverse customer base with access to advanced blockchain technologies.
  • Morpheus Labs will use Coinweb's platform as a preferred supplier to access blockchain technology, with the aim of facilitating the immediate development of projects directly on Coinweb, from startups to household names.
  • This collaboration empowers developers within the Morpheus Labs ecosystem, enabling them to leverage the full potential of Web3 technologies and drive innovation across diverse industries.

Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study

Retrieved on: 
Thursday, February 22, 2024

THE WOODLANDS, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has completed selection of Principal Investigators for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. Additionally, the Principal Investigators have successfully completed training for the PoC study.

Key Points: 
  • Additionally, the Principal Investigators have successfully completed training for the PoC study.
  • “We are building important momentum with the advancement of our PoC human clinical study.
  • We worked diligently to identify and secure our Principal Investigators for the study and have completed the training for this first study ever to evaluate RF ablation in a transvascular approach.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the study.

United States Medical Diagnostics Research Report 2024: Market Impacts of Surging Adoption of Healthcare Wearables and Rising Integration with Artificial Intelligence - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024

A few notable trends include surging adoption of healthcare related devices like wearables, emergence of various pandemic diseases, rising integration with Artificial Intelligence and growing awareness for personalized medicine.

Key Points: 
  • A few notable trends include surging adoption of healthcare related devices like wearables, emergence of various pandemic diseases, rising integration with Artificial Intelligence and growing awareness for personalized medicine.
  • The U.S. medical diagnostics market has been segmented on the basis of type, product type and end-users.
  • Depending on the product type, the U.S. medical diagnostics market can be segmented into reagents, instruments and software & services.
  • The report provides a comprehensive analysis of the U.S. medical diagnostics market segmented on the basis of type, product type, end users and region.